ZIOPHARM Oncology Inc.

NAS: ZIOP

GO
/marketstate/country/us

After Hours

 --Real time quotes

Jun 1, 2020, 4:25 p.m.

/zigman2/quotes/200291745/composite

$

3.05

Change

+0.04 +1.33%

Volume

Volume 90,858

Real time quotes

/zigman2/quotes/200291745/composite

Today's close

$ 2.96

$ 3.01

Change

+0.05 +1.69%

Day low

Day high

$2.86

$3.07

Open

52 week low

52 week high

$1.80

$7.25

Open

Annual Financials for ZIOPHARM Oncology Inc.

Operating Activities

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Net Income before Extraordinaries (120.09M)(165.3M)(54.32M)(53.12M)(117.8M)
Depreciation, Depletion & Amortization 357,000290,000369,000575,000629,000
Depreciation and Depletion 357,000290,000369,000575,000629,000
Amortization of Intangible Assets -----
Deferred Taxes & Investment Tax Credit -----
Deferred Taxes -----
Investment Tax Credit -----
Other Funds 75.28M127.6M9.75M7.38M68.09M
Funds from Operations (44.45M)(37.41M)(44.21M)(45.17M)(49.08M)
Extraordinaries -----
Changes in Working Capital 44.44M(20.92M)(10.46M)(4.29M)8.22M
Receivables (301,000)425,0002,000(1.85M)(1.47M)
Accounts Payable 4,000(1.85M)4.26M(3.71M)199,000
Other Assets/Liabilities 43.01M(19.69M)(15.53M)2.41M7.76M
Net Operating Cash Flow (10,000)(58.33M)(54.67M)(49.46M)(40.85M)

Investing Activities

20152016201720182019 5-year trend
Capital Expenditures (412,000)(551,000)(737,000)(459,000)(284,000)
Capital Expenditures (Fixed Assets) (412,000)(551,000)(737,000)(459,000)(284,000)
Capital Expenditures (Other Assets) -----
Net Assets from Acquisitions -----
Sale of Fixed Assets & Businesses -----
Purchase/Sale of Investments -----
Purchase of Investments -----
Sale/Maturity of Investments -----
Other Uses -----
Other Sources -----
Net Investing Cash Flow (412,000)(551,000)(737,000)(459,000)(284,000)

Financing Activities

20152016201720182019 5-year trend
Cash Dividends Paid - Total -----
Common Dividends -----
Preferred Dividends -----
Change in Capital Stock 98.34M(788,000)45.3M45.72M59.15M
Repurchase of Common & Preferred Stk. (552,000)(1.5M)(2.06M)(1.62M)(653,000)
Sale of Common & Preferred Stock 98.89M714,00047.36M47.34M59.8M
Proceeds from Stock Options 94.32M-47.27M47.1M6.09M
Other Proceeds from Sale of Stock 4.57M714,00088,000240,00053.72M
Issuance/Reduction of Debt, Net -----
Change in Current Debt -----
Change in Long-Term Debt -----
Issuance of Long-Term Debt -----
Reduction in Long-Term Debt -----
Other Funds ---(5.41M)-
Other Uses ---(5.41M)-
Other Sources -----
Net Financing Cash Flow 98.34M(788,000)45.3M40.31M59.15M
Exchange Rate Effect -----
Miscellaneous Funds -----
Net Change in Cash 97.91M(59.66M)(10.11M)(9.61M)18.01M
Free Cash Flow (422,000)(58.88M)(55.41M)(49.92M)(41.14M)
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.